Italy's Snia faces $580 million takeover
This article was originally published in Clinica
Executive Summary
Snia, the Italian biomedical and chemicals group specialising in cardiovascular implantable devices, is facing a E670 million ($578 million) takeover, after unlisted Italian holding company Bios announced on January 29 a bid of E1.80 per share for the 71.2% of stock it does not own. Shares in the company were standing at around E1.90 as Clinica went to press, having risen from around E1.20 in mid-November.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.